Longfellow Real Estate Partners Exits Debut NYC Project: The $86.9 Million Sale of the Hatch Life Sciences Building

In a significant move for the New York City commercial real estate market, Longfellow Real Estate Partners—a prominent player in the life sciences development sector—has finalized the sale of its flagship New York City project. The Hatch Life Sciences Building, situated at 43-10 23rd Street in Long Island City, Queens, was offloaded for $86.9 million, according to city property records filed this past Friday.

The transaction marks the end of an ambitious, albeit challenging, chapter for the developer. Acquired in 2021 as a cornerstone of the firm’s expansion into the New York market, the property was intended to serve as a beacon for the borough’s growing biotech ecosystem. However, the final sale price represents a notable discount from the firm’s initial acquisition cost, highlighting the complex macroeconomic headwinds currently facing office-to-lab conversions in urban centers.

The buyer, an entity identified as 4310 23 St and represented by Jack Guttman of Pearl Realty Management, has yet to disclose its specific intentions for the site.

Chronology of the Hatch Life Sciences Project

The 2021 Acquisition and Vision

In late 2021, Longfellow Real Estate Partners, under the leadership of CEO and co-founder Adam Sichol, made a high-profile entry into the New York City market. In a joint venture with Sculptor Real Estate, led by Steven Orbuch, the firm purchased the industrial property at 43-10 23rd Street for $92.5 million.

The building, a former parachute manufacturing plant, was envisioned as a state-of-the-art facility designed to cater to the burgeoning demand for laboratory space from pharmaceutical companies, academic institutions, and biotech startups. The developers announced an aggressive capital improvement plan, pledging an additional $120 million to gut-renovate the structure and transform it into a modern life sciences hub.

The Development Phase (2022–2024)

The transformation of the seven-story structure was a massive undertaking. Over the course of three years, the site underwent a rigorous conversion process. By the time Commercial Observer conducted a site visit in early 2024, construction was effectively nearing completion.

The final footprint of the Hatch Life Sciences Building totaled approximately 208,000 square feet. The design prioritized modularity and flexibility, featuring:

Pre-built Lab Suites: Designed to allow biotech firms to bypass the lengthy build-out process.
Modular Research Space: Infrastructure capable of accommodating high-density laboratory equipment and specialized ventilation systems.
Flexible Office Areas: Designed to foster collaboration between scientific research teams and administrative staff.

The Market Shift and Divestment

Despite the high-quality infrastructure and the strategic location in Long Island City—an area previously identified as a prime candidate for the city’s life sciences "corridor"—the project faced mounting pressure. The post-pandemic shift in interest rates, a cooling in venture capital funding for early-stage biotech firms, and a general tightening of the commercial real estate market likely contributed to the decision to sell. The $86.9 million price point, falling below the initial $92.5 million acquisition cost (excluding the $120 million investment), underscores the difficulty developers have faced in recouping capital for specialized lab projects in the current economic climate.

Pearl Realty Management’s Expanding Footprint

The buyer, Pearl Realty Management, has been quietly consolidating a significant portfolio in the Long Island City area. Jack Guttman, acting on behalf of the firm, has been instrumental in a string of recent acquisitions that suggest a long-term bullish outlook on the Queens commercial market.

Recent acquisitions by Pearl Realty Management include:

The Standard Motors Product Building: Located at 37-18 Northern Boulevard, this acquisition was valued at approximately $42 million.
21-02 49th Avenue: A former office building previously held by BrightSpire Capital, which Pearl Realty acquired for $28 million.

These strategic acquisitions point to a diversified approach. While Longfellow specialized in life sciences, Pearl Realty’s broader activity suggests they may be looking at a wider range of uses for their growing portfolio, or perhaps a more conservative lease-up strategy than the ambitious life sciences model originally proposed by Longfellow.

The State of the New York Life Sciences Sector

The sale of the Hatch building provides a case study for the broader New York City life sciences market. In recent years, city and state governments have pushed initiatives to turn NYC into a global hub for biotech, citing its proximity to top-tier research hospitals and universities.

However, the "flight to quality" and the high cost of specialized infrastructure have created a bottleneck. While major projects in Manhattan (such as those in Kips Bay and Long Island City) continue to attract investment, the speculative nature of converting older industrial buildings into laboratory space has proven to be a high-risk endeavor.

Industry analysts note that laboratory space requires specific "heavy" infrastructure—high-capacity electrical grids, advanced HVAC systems, and specialized plumbing—that makes these buildings significantly more expensive to operate than traditional office space. When the tenant demand slows, the carrying costs of these properties become an immediate burden on developers like Longfellow.

Official Responses and Stakeholder Silence

To date, both the buyer and the seller have remained tight-lipped regarding the details of the transaction. Representatives for Pearl Realty Management did not respond to multiple inquiries regarding their future plans for the 43-10 23rd Street site, nor did they clarify if the building would retain its life sciences designation.

Similarly, Longfellow Real Estate Partners and Sculptor Real Estate declined to provide specific commentary on the financial implications of the sale or the decision to divest from their debut NYC asset. The lack of public statements is common in such transactions, yet it leaves industry watchers to speculate on whether this represents a total retreat from the New York market for Longfellow, or merely a strategic portfolio rebalancing.

Implications for the Future of Long Island City

The acquisition by Pearl Realty Management is a clear signal that institutional capital remains interested in Long Island City, even if the appetite for speculative biotech development has waned.

For the neighborhood, the implications are twofold:

Shift in Use: If the new owners choose to pivot away from lab space, it could signal a broader cooling in the biotech real estate sector, leading to a shift toward traditional office or mixed-use developments.
Market Valuation: The fact that the building sold for less than its initial acquisition price (before accounting for the $120 million renovation) may serve as a benchmark for other developers currently holding distressed or under-leased life sciences assets. It suggests that the market is recalibrating expectations for property values in the outer boroughs.

As the dust settles on the Hatch transaction, market participants will be watching the next move from the Pearl Realty team. Whether they continue to operate the property as a life sciences facility or repurpose it entirely will provide a litmus test for the viability of specialized lab infrastructure in Queens.

In the meantime, Longfellow Real Estate Partners continues to operate in other major markets, though the sale of their debut New York project serves as a reminder that even the most well-capitalized firms are not immune to the volatility of the contemporary commercial real estate landscape. The Hatch building, once poised to be a center of innovation, now enters a new phase of ownership, leaving the industry to wonder what shape that innovation—or lack thereof—will take in the coming years.